Humacyte Director buys 30,000 shares, following superior Phase 3 trial data

Humacyte published one-year results from its V007 Phase 3 trial in The Lancet Digital Health on August 19. The study evaluated the company’s acellular tissue engineered vessel (ATEV) for hemodialysis access. Data showed the ATEV outperformed the standard of care, particularly in high-risk patient populations.

Director Keith Anthony Jones purchased 30,000 shares of Humacyte stock on August 19, 2026. The transaction totaled $17,700. This insider purchase followed the publication of the positive clinical results.

Humacyte recently received a Nasdaq notice because its stock price fell below the minimum bid requirement.